[HTML][HTML] Diagnostic and prognostic performance of neurofilaments in ALS
K Poesen, P Van Damme - Frontiers in neurology, 2019 - frontiersin.org
Frontiers in neurology, 2019•frontiersin.org
There is a need for biomarkers for amyotrophic lateral sclerosis (ALS), to support the
diagnosis of the disease, to predict disease progression and to track disease activity and
treatment responses. Over the last decade multiple studies have investigated the potential of
neurofilament levels, both in cerebrospinal fluid and blood, as biomarker for ALS. The most
widely studied neurofilament subunits are neurofilament light chain (NfL) and
phosphorylated neurofilament heavy chain (pNfH). Neurofilament levels are reflecting …
diagnosis of the disease, to predict disease progression and to track disease activity and
treatment responses. Over the last decade multiple studies have investigated the potential of
neurofilament levels, both in cerebrospinal fluid and blood, as biomarker for ALS. The most
widely studied neurofilament subunits are neurofilament light chain (NfL) and
phosphorylated neurofilament heavy chain (pNfH). Neurofilament levels are reflecting …
There is a need for biomarkers for amyotrophic lateral sclerosis (ALS), to support the diagnosis of the disease, to predict disease progression and to track disease activity and treatment responses. Over the last decade multiple studies have investigated the potential of neurofilament levels, both in cerebrospinal fluid and blood, as biomarker for ALS. The most widely studied neurofilament subunits are neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH). Neurofilament levels are reflecting neuronal injury and therefore potentially of value in ALS and other neurological disorders. In this mini-review, we summarize and discuss the available evidence about neurofilaments as diagnostic and prognostic biomarker for human ALS.
Frontiers